Atrial fibrillation (AF) is a leading cause of cardiovascular disease worldwide with a projected prevalence to exceed 10 million people by 2050 . Research demonstrates that atrial fibrillation is associated with a higher risk of all-cause mortality, and a significantly higher risk of stroke and cardiac events in women . With trends predicting sex differences in atrial fibrillation associated outcomes, it is reasonable to assume that sex differences may also play an important role on selecting treatments, including percutaneous left atrial appendage occlusion (LAAO) implantation. LAAO implantation has been shown to be a safe alternative for patients with AF who have contraindications to anticoagulation.